Novartis NOVN.SW · CHF

Its shares trade on SIX under the ticker NOVN.SW. It has been listed since 7 May 2001. In the fiscal year to 31 December 2025, it reported revenue of $46.49bn and net income of $11.92bn. At that date it held total assets of $94.00bn and shareholders' equity of $37.52bn.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Basel, Basel-Stadt. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Vasant NarasimhanChief Executive Officer, Member of the Executive CommitteeCHF 19.2m
• Mr. Giovanni CaforioChairman of the Board, since 2025
• Dr. Simon MoroneyIndependent Non-Executive Vice Chairman of the BoardCHF 460,000
• Mr. Harry KirschChief Financial Officer, Member of the Executive CommitteeCHF 5.4m
• Dr. Shreeram AradhyePresident - Global Drug Development and Chief Medical Officer, Member of the Executive CommitteeCHF 3.4m
• Mr. Victor BultoPresident - US, Member of the Executive Committee$2.9m
• Mr. Patrick HorberPresident - International, Member of the Executive Committee
• Dr. Steffen LangPresident - Operations, Member of the Executive CommitteeCHF 3.9m
• Dr. Fiona MarshallPresident - Biomedical Research, Member of the Executive Committee$4.4m
• Dr. Klaus MoosmayerChief Ethics, Risk and Compliance Officer, Member of the Executive CommitteeCHF 2.5m
• Mr. Aaron GalChief Strategy and Growth Officer, Member of the Executive CommitteeCHF 5.3m
• Ms. Karen HaleChief Legal Officer, Member of the Executive CommitteeCHF 3.8m

Overall

84

Environment

75

Social

94

Governance

85

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.